FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

21 letters match. Newest first.

  1. FairyGene, Inc.

    FDA cites FairyGene, a Bristol, PA contract manufacturer, for unsanitary facility and cleaning practices and for selling five unapproved drug balms.

    High risk
  2. Cosmetic Manufacturers Pty Ltd.

    FDA warned Cosmetic Manufacturers Pty Ltd. that its Australian drug site was adulterated due to CGMP violations and placed its drugs on import alert.

    High risk
  3. Winder Laboratories, LLC

    FDA warns Winder Laboratories of adulterated prescription drugs due to cleaning and facility failures.

    High risk
  4. Kenil Healthcare Private Limited

    FDA warns Kenil Healthcare over adulterated drugs from India due to cleaning, packaging, and quality failures.

    High risk
  5. Dyno Manufacturing, Inc.

    Dyno Manufacturing’s OTC hand sanitizer and antibacterial soap drugs lacked raw-material identity testing and other required manufacturing controls.

    High risk
  6. AmWiner & Raphe Holdings, LLC dba rapheGenerics Corp

    FDA cited rapheGenerics for manufacturing-quality failures and unapproved minoxidil hair regrowth drugs.

    High risk
  7. Accupack Midwest, Inc.

    Accupack Midwest, an over-the-counter drug contract manufacturer, lacked adequate water controls and process validation.

    High risk
  8. LS Promotions Inc.

    LS Promotions Inc. failed to adequately test and validate its OTC sunscreens, lip balm and hand sanitizer, making them adulterated drugs.

    High risk
  9. Aqualex Co., Ltd.

    Aqualex, a Korean contract manufacturer, was cited for manufacturing failures and an unapproved OTC sunscreen with misleading labeling.

    High risk
  10. Handock Cosmetics Co., Ltd.

    FDA warns Handock Cosmetics over manufacturing quality failures and unapproved/mislabeled hand sanitizers from South Korea.

    High risk
  11. Caltag Medsystems Ltd

    FDA warned Caltag Medsystems over quality-system failures in making TransFix/EDTA Vacuum Blood Collection Tubes.

    Medium
  12. Lex Inc.

    FDA warns Lex Inc. of Medley, Florida, that its over-the-counter drugs are adulterated because manufacturing rules were not met, including missing toxic-ingredient testing.

    High risk
  13. Cosmetic Science Laboratories LLC

    FDA warned Cosmetic Science Laboratories about OTC sunscreen drugs made without required manufacturing controls.

    High risk
  14. Wintech Medipro LLC

    FDA warns Wintech Medipro over unapproved surgical masks and broad quality system failures.

    High risk
  15. American Cleaning Solutions

    FDA warned American Cleaning Solutions after a 2022 inspection found hand sanitizer made with inadequate cleaning, unvalidated processes, and substituted ethanol.

    High risk
  16. Verde Cosmetic Labs LLC

    FDA warned Verde Cosmetic Labs after an inspection found inadequate CGMP controls for OTC topical drugs, including cleaning and water system failures.

    High risk
  17. Colorful Products Corporation

    FDA warned Colorful Products Corporation about serious current good manufacturing practice (CGMP) failures for its over-the-counter topical drugs and hand sanitizers.

    High risk
  18. Indiana Chem-Port

    Indiana Chem-Port API manufacturer cited for CGMP deviations including dirty equipment, unvalidated processes, and cleaning failures.

    High risk
  19. Proquimes S A Productos Quimicos Especializados S.A.

    FDA warned Proquimes S.A. that its active pharmaceutical ingredient manufacturing violated current good manufacturing practice (CGMP) because process, equipment, and cleaning validation were missing.

    High risk
  20. Honest Globe, Inc.

    FDA cited Honest Globe for manufacturing-quality failures and for selling unapproved CBD pain-relief drugs.

    High risk
  21. Dibar Nutricional S. de R.L. de C.V.

    Dibar Nutricional's OTC drugs drew FDA CGMP violations and an import alert over missing testing.

    High risk